Breaking Finance News

Verastem (NDAQ:VSTM) target price raised to $2.00, issued a report today by Cantor Fitzgerald

Verastem (NDAQ:VSTM) had its target price raised to $2.00 by Cantor Fitzgerald in a report released 6/08/2017. The new target price indicates a possible downside of -0.09% based on the company's last stock close price.

Previously on 5/12/2017, Cann reported about Verastem (NDAQ:VSTM) raised the target price from $0.00 to $2.00. At the time, this indicated a possible downside of -0.18%.

Yesterday Verastem (NDAQ:VSTM) traded -2.81% lower at $2.19. The company’s 50-day moving average is $4.59 and its 200-day moving average is $3.09. The last stock close price is down 45.41% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 430,753 shares of the stock were exchanged, down from an average trading volume of 1,329,690

See Chart Below

Verastem (NDAQ:VSTM)

Verastem has a 52 week low of $1.05 and a 52 week high of $5.71 The company’s market cap is currently $0.

General Information About Verastem (NDAQ:VSTM)

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.